Francis Medical has taken an undisclosed strategic investment from JJDC, the venture arm of Johnson & Johnson. The Minnesota company said on November 11 that the money covers regulatory work, commercial scaling, market access and physician training.
Francis plans to file a PMA for Vanquish, its water vapor ablation system, in clinically localized prostate cancer. Vanquish already holds FDA authorization for thermal ablation of targeted prostate tissue, granted in November 2025. The cancer indication is the larger claim and the harder filing.
The VAPOR 2 study (NCT05683691) is testing Vanquish in intermediate-risk Gleason Grade Group 2 disease. Six-month biopsy data from 110 of the 235 enrolled patients showed elimination of targeted, MRI-visible disease of GGG2 or higher in 91 percent after a single procedure. A strategic investor paying for market access before the PMA goes in is a reasonable read on how that filing is expected to land.